Fiona Stevens

Ligand Licenses VER250840 to Cumulus Oncology

Ligand Pharmaceuticals has announced the signing of a license agreement granting Cumulus Oncology exclusive worldwide rights to develop and commercialise VER250840, a novel, oral, selective, preclinical Chk1 Kinase Inhibitor discovered using Ligand’s Vernalis Design Platform (VDP). Under the terms of the agreement, Ligand will receive an upfront license fee, and...

Read more

Closed Loop Medicine Raises £2.1M Pre-Series A

GJE client Closed Loop Medicine raised £2.1M in venture capital funding. The raise for the Cambridge-based health tech start-up was from Longwall Ventures Partners amongst other investment groups. Closed Loop Medicine is a start-up that helps doctors and healthcare providers deliver personalised treatment regimens by combining proven drug treatments with...

Read more

Imago BioSciences announces $40M Series B financing led by Omega Funds

On 21 March, Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, announced a $40 million Series B financing led by Omega Funds, a GJE client and leading international investment firm that creates and invests in life sciences companies. Proceeds from the financing will be used...

Read more

AI Generated Innovation

On Thursday 14 March, Fiona Stevens and Peter Finnie will attend the AI Generated Innovation event, hosted by the AIPPI UK. The event has been organised in recognition of the increasing reliance on AI and machine learning across many different technical fields. Fiona will speak on a panel with GJE...

Read more

LSX Nordic Congress

On Thursday 30 August, Peter Finnie and Fiona Stevens will be attending the LSX Nordic Congress in Stockholm. This exclusive congress for life science senior executives is an opportunity to network and will provide valuable insight into strategies, solutions, and contacts that life science companies need to enable more effective...

Read more